bluebird bio to Present at Two Investor Conferences in November

CAMBRIDGE, Mass.–(BUSINESS WIRE)– bluebird bio, Inc. (Nasdaq:
BLUE), a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic diseases and T
cell-based immunotherapies for cancer, today announced that members of
the management team will present at the following upcoming investor
conferences:

• Credit Suisse 25^th Annual Healthcare Conference on November
  8, 2016, at 3:00 pm PT at the Phoenician in Scottsdale, Arizona
• Piper Jaffray 28^th Annual Healthcare Conference on November
  29, 2016, at 12:00 pm ET the Lotte New York Palace in New York

To access the live webcast of bluebird bio’s presentations, please visit
the “Events & Presentations” page within the Investors and Media section
of the bluebird bio website at http://investor.bluebirdbio.com.
Replays of the webcasts will be available on the bluebird bio website
for 90 days following the conferences.

About bluebird bio, Inc.

With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio’s gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a
Phase 2/3 study, called the Starbeam Study, for the treatment of
cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product
candidate, currently in four clinical studies for the treatment of
transfusion-dependent β-thalassemia and severe sickle cell disease.
bluebird bio’s oncology pipeline is built upon the company’s leadership
in lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program
partnered with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.

bluebird bio has operations in Cambridge, Massachusetts; Seattle,
Washington; and Paris, France.

Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, risks that the
current or planned clinical trials of the LentiGlobin drug product will
be insufficient to support regulatory submissions or marketing approval
in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or more of
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent quarterly report on
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the Securities
and Exchange Commission. All information in this press release is as of
the date of the release, and bluebird bio undertakes no duty to update
this information unless required by law.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006311/en/